Platelet-derived growth factor (PDGF) is a potent moderator of soft tissue repair through induction of the inflammatory phase of repair and subsequent enhanced collagen deposition. We examined the effect of recombinant BB homodimer PDGF (rPDGF-BB) applied to rat craniotomy defects, treated with and without bovine osteogenin (OG), to see if bone regeneration would be stimulated. Implants containing 0, 20 
Introduction
There is growing evidence that growth factors such as PDGF contribute to bone wound repair by attracting and stimulating proliferation of wound-healing cells and bone progenitor cells ( 1) . Studies in vitro indicate that PDGF is chemotactic for neutrophils, monocytes, and fibroblasts (2) (3) (4) , and stimulates the proliferation and activity of fetal (5, 6) and mature bone cells (7, 8) . In vivo, PDGF stimulates granulation tissue formation in PDGF/collagen-treated chambers implanted subcutaneously (9, 10) . Furthermore, PDGF stimulates healing of skin incisions and excisions by increasing inflammatory cell infiltration, provisional matrix formation, collagen deposition, and neovascularization (1 1-17).
The initial stages ofbone wound healing are similar to those observed in soft tissue. Blood from the marrow cavity and adjacent soft tissues fills the wound and a clot forms, followed by inflammation and granulation tissue formation. Progenitor cells are drawn to the wound, proliferate, and differentiate to cartilage-and bone-forming cells. The wound is revascularized, matrix is elaborated and mineralized, and hematopoiesis is restored. Many of the initial processes of bone wound repair, such as infiltration and proliferation of precursor cells, could be stimulated by PDGF, which might accelerate the entire bone repair process.
Few studies have tested the effect of PDGF on bone regeneration in vivo. In two studies, PDGF enhanced demineralized bone matrix-induced ectopic cartilage and bone formation ( 18, 19) . However, PDGF had no effect when injected daily onto the periosteum of parietal bones of newborn rats, though similar treatment with transforming growth factor-f doubled the thickness of calvariae at injection sites after 12 d (20, 21) .
Therapeutic concentrations of soluble proteins are difficult to maintain within wound beds, as factors may be washed away or diluted by extracellular fluids. Periodic addition of factors requires invasive procedures, such as injection (21-23) or infusion (24, 25) , which are clinically impractical and may exacerbate the wound. Insoluble collagenous bone matrix (ICBM)' has been used successfully as a carrier for bone-inductive proteins in vivo (26) (27) (28) . The affinity of PDGF towards negatively charged extracellular matrix proteins present in ICBM (29) made it an ideal candidate for a biological carrier. However, as the activity of PDGF bound to matrix proteins is uncertain, this affinity had to be considered in estimating effective doses of PDGF.
Our laboratory has developed experimental intraosseous wound models, critical size defects (CSDs), for evaluating potential bone regenerative materials. If left untreated, CSDs will not heal by bone formation within the lifetime of the animal (30) . The 8-mm rat craniotomy is a CSD that heals not by bone formation but rather by fibrous union (31 , in deionized water, were added to 25 mg ICBM in 2-ml microcentrifuge tubes (8-mm internal diameter). The proteins were precipitated by the addition of dry ice-chilled absolute ethanol (35) . The pellets obtained by centrifugation at 12,000 rpm for 15 min were washed twice with 85% ethanol, then dried by vacuum centrifugation. rPDGF-BB in 0.25% HSA, 10 mM NaOAc, 0.15 M NaCl was added to the dried pellets, tapped to ensure uniform distribution, then dried by vacuum centrifugation. Each sample received identical amounts of carrier solutions.
To measure rPDGF-BB release from ICBM in vitro, seven pellets were made as described above, without osteogenin. The dried pellets containing 54 gg '251-rPDGF-BB (29,000 cpm/,g), chondroitin sulfate, and buffer salts were rehydrated with 0.5 ml 0.25% HSA, then placed in an oscillating heating block at 370C. Radioactivity of 10-,ul aliquots was measured at designated times. Aliquots were frozen and subsequently assayed for bioactivity (mitogen assay) as described ( 11 ) .
Surgical implantation. 144 male Long-Evans rats, 28-35 d old, were randomly assigned to treatment groups. 8-mm craniotomy defects were created in anesthetized rats as described previously (28) . Implants were placed only into nonbleeding wounds. Soft tissue was closed with surgical staples. 28 d later, the rats were killed by CO2 asphyxiation. The fronto-occipital-parietal complex was removed and immersed in 70% ethanol.
Radiomorphometry. Specimens were radiographed with ultra-highcontrast mammography x-ray film (X-Omat TL; Eastman Kodak Company, Rochester, NY) within 24 h of retrieval. Radiopacity was measured by computer-assisted image analysis (28, 36) , and expressed as an area percentage of the 50.26-mm2 defect.
Histomorphometry. Specimens were dehydrated with increasing concentrations ofethanol, then embedded in polymethylmethacrylate.
Consecutive coronal sections, 4.5-5.0 Mm thick, were stained with von Kossa stain. The area of new bone calcium within defects was quantified by computer-assisted image analysis (28, 36) .
Statistical analyses. Data were analyzed by graphics (Cricket Graph; Cricket Software, Malvern, PA) and statistical (Statview II; Abacus Concepts, Berkeley, CA) computer software packages. We predicted that both OG and rPDGF-BB would have a positive, dose-related effect on bone regeneration within the defect site. Therefore, multiple regression analysis was performed on the data set. Fisher's protected least significant difference test was used to detect significant differences between the means of rPDGF-BB-treated and untreated groups within each dose of OG. Statistical significance was established at P < 0.05.
Results
An initial dose-response study allowed determination of the effective dose range of partially purified OG. Fig. 1 11 died from anaesthesia or surgical complications within the first 4 h after surgery. Another rat was found dead the following morning. The remaining were ambulatory, alert, and responsive. 11 d after surgery, a subcutaneous, cyst-like mass centered over the experimental defect was seen in 21 animals. This response had not been noted in previous experiments testing bone-inductive materials, including OG, and no masses were noted in animals treated with OG alone. The cyst-like masses varied in size and were scored on a four-point scale, 4 having a vertical elevation from the skull of 2 cm (Table I ). The scorer was blinded to treatment groups. Multiple regression analysis showed that both rPDGF-BB and OG had significant dose effects on the size ofthe masses. However, the effect of OG was significant only at the highest dose of rPDGF-BB, whereas . .. of the total area of the 8-mm circle. Data represent mean and SD of 6-11 defects/dose. Regression analysis showed the dose effect to be significant (P < 0.05). (Fig. 3 A) . The tissue was turgid but elastic and was easily dissected from the overlying skin. Removal ofthe cranium and attached tissue mass revealed dura that appeared normal and cerebral cortices without edema, necrosis, or inflammatory exudate. No fluid leaked from the mass when it was necropsied.
Histological examination (Fig. 3 B) revealed a core of proteinaceous fluid and erythrocyte ghosts with fibrin strands and occasional macrophages and neutrophils. The mass was encapsulated by fibrous tissue comprised of loose extracellular matrix admixed with macrophages and neutrophils. The ICBM had been displaced lateral and superior to the temporal crests of the parietal bones.
The masses resolved within the following 2 wk. At necropsy, however, experimental sites revealed fluid accumulation in several cases treated with 200 ,tg rPDGF-BB. In two cases, clear yellow fluid had accumulated within the soft tissue superior to the defect site. In one case, sero-sanguineous fluid was observed supradurally, causing compression necrosis of a section of the cerebral cortex. Three additional sites treated with 200 ,g rPDGF-BB revealed focal necrosis of the cerebral cortex. Histologic examination confirmed compression and proliferation of the meninges. Another specimen had dilation ofthe right lateral ventricle, while in another there was evidence of hemorrhage into the lateral ventricle and into the subarachnoid space. There was a focal area ofmineralization within one ventricle.
Radio-and histomorphometry (Fig. 4, A and B) showed that OG had a positive dose effect on both percent radiopacity and regeneration of calcified tissue, whereas rPDGF-BB has a significant, negative dose effect only on percent radiopacity (P < 0.05). Comparisons of individual means indicated that all doses of rPDGF-BB inhibited OG-induced bone regeneration when the measured parameter was the percent radiopacity of the 8-mm defect (Fig. 4 A) . Measurements of new bone in coronal sections ofdefect sites indicated that at the higher dose ofOG, only the 60-,gg dose ofrPDGF-BB was inhibitory (Fig. 4  B) ing across the critical-sized defect (Fig. 5 B) , infrequent islands of fibrocartilage, and occasional foci of cartilage. In addition, woven bone appeared to predominate over lamellar bone when (Fig. 5 C) . Osteoblasts were few in number with rare osteoclasts. Fibrocartilage was observed subjacent to the pericranial connective tissue lining in two cases. There was nothing unusual about either the cellular or stromal elements of the tissue.
60 Ag rPDGF-BB/ICBM. Observations for this treatment group were essentially identical to those described for 20 Mg PDGF. Occasionally, remnants of a supradural hematoma were evident in a few specimens with fibrin strands and minimal number of macrophages. The granulation tissue consisted of numerous swirls of collagenous fibers, fibroblasts with robust nuclei, and rich neovascularization. Again, there was either little or no new bone. Osteoblastic activity was confined to some pericranial aspects ofthe host bone; it was not associated with the ICBM particles containing PDGF. Isolated islands of fibrocartilage were apparent.
200 Ag rPDGF-BB/ICBM. There were numerous remnants of ICBM throughout the defect (Fig. 5 D) , wrapped in a loose web ofconnective tissue with a moderate number offibroblasts. New bone formation from host margins was sparse. One specimen in this group displayed an isolated area of fibrocartilage mid-defect along the pericranial aspect. Neovasculanzation was rich, with numerous venules, arterioles, and capillaries.
30 Mg (Fig. 5 E) . Furthermore, new bone formation seemed more subdued than that observed in other OG treatments.
30 ,g OG/200 ,g rPDGF-BB/ICBM. Dense connective bridging spanned the 8-mm craniotomy wounds displaying scant new bone formation associated with ICBM. Bone regeneration occurred predominantly at host wound edges in a centripetal direction. There was more woven bone pericranially than along the dura, indicating increased activity in this zone in contrast to other areas ofthe healing wound. Several specimens revealed a dense connective capsule surrounding a resolving hematoma.
150 Mg OG/20 ug rPDGF-BB/ICBM. There were bone bridges across the craniotomies consisting of condensing woven and lamellar bone, rich marrow, active osteoblasts, and subjacent osteoid (Fig. 5 F-i) . Numerous capillaries, venules, and arterioles were seen along the dura; a slightly greater amount was observed pericranially. Residual fragments of ICBM were amalgamated within the newly forming bone with nidi ofindependent zones ofnew bone (Fig. 5 F-2 The precise mode of action of osteogenin and related bone morphogenetic protein(s) is not known. However, it is likely that the responding mesenchymal stem cells have the potential to proceed on at least two different lineages: soft tissue or hard skeletal tissue. In view of this, there is a delicate balance that is modified by PDGF-BB toward a predominantly soft tissue response. This is borne out by the observed lack of pronounced inhibitory effect of PDGF-BB when higher doses of osteogenin were used.
These data, suggesting that PDGF is not effective in enhancing bone regeneration at the dosage levels tested, do not refute a possible physiological role for PDGF in bone repair. Recent work (Chen, G., and A. H. Reddi, unpublished observations) has indicated that low doses (50 ng) of PDGF-BB combined with 30 Aig of OG act synergistically to elicit heterotopic bone formation. Indeed, localization of PDGF within osteoblasts suggests a role in bone homeostasis. Identification of PDGF receptor-bearing cells (40, 41 ) in models of hard tissue repair will be important in determining targets ofPDGF. In addition, positive effects of PDGF may become manifest after development ofa delivery system that would allow release of optimal doses of PDGF at optimal times during healing.
